Reason for request
- Key points
Favourable opinion for reimbursement in the maintenance treatment of patients with advanced BRCA-mutated ovarian cancer who have responded to first-line chemotherapy.
- What therapeutic improvement?
LYNPARZA provides a minor therapeutic improvement in the treatment of ovarian cancer.
- Role in the care pathway?
The treatment of ovarian cancer is mainly based on initial surgery, followed by standard first-line chemotherapy for advanced-stage cancers. Some guidelines recommend the use of AVASTIN (bevacizumab) in combination with chemotherapy then as maintenance monotherapy in patients with a poor prognosis.
Role of the medicinal product in the care pathway
LYNPARZA is a maintenance treatment for adult patients with advanced BRCA-mutated ovarian cancer, who have responded to first-line platinum-based chemotherapy.
- Special recommendations
The Committee reminds the fact that there are no data concerning the use of LYNPARZA as monotherapy in the maintenance treatment of patients treated with first-line chemotherapy combined with bevacizumab (AVASTIN).
The clinical benefit (CB) of LYNPARZA is substantial in the MA indication.
Clinical Added Value